248 related articles for article (PubMed ID: 29023824)
21. Centrosomal abnormalities characterize human and rodent cystic cholangiocytes and are associated with Cdc25A overexpression.
Masyuk TV; Lee SO; Radtke BN; Stroope AJ; Huang B; Banales JM; Masyuk AI; Splinter PL; Gradilone SA; Gajdos GB; LaRusso NF
Am J Pathol; 2014 Jan; 184(1):110-21. PubMed ID: 24211536
[TBL] [Abstract][Full Text] [Related]
22. Polycystic Liver Disease: Advances in Understanding and Treatment.
Masyuk TV; Masyuk AI; LaRusso NF
Annu Rev Pathol; 2022 Jan; 17():251-269. PubMed ID: 34724412
[TBL] [Abstract][Full Text] [Related]
23. Blockade of Hedgehog Signaling Attenuates Biliary Cystogenesis in the Polycystic Kidney (PCK) Rat.
Sato Y; Yamamura M; Sasaki M; Harada K
Am J Pathol; 2018 Oct; 188(10):2251-2263. PubMed ID: 30036521
[TBL] [Abstract][Full Text] [Related]
24. MicroRNA15a modulates expression of the cell-cycle regulator Cdc25A and affects hepatic cystogenesis in a rat model of polycystic kidney disease.
Lee SO; Masyuk T; Splinter P; Banales JM; Masyuk A; Stroope A; Larusso N
J Clin Invest; 2008 Nov; 118(11):3714-24. PubMed ID: 18949056
[TBL] [Abstract][Full Text] [Related]
25. Pasireotide is more effective than octreotide in reducing hepatorenal cystogenesis in rodents with polycystic kidney and liver diseases.
Masyuk TV; Radtke BN; Stroope AJ; Banales JM; Gradilone SA; Huang B; Masyuk AI; Hogan MC; Torres VE; Larusso NF
Hepatology; 2013 Jul; 58(1):409-21. PubMed ID: 23172758
[TBL] [Abstract][Full Text] [Related]
26. An update on the pathophysiology and management of polycystic liver disease.
Wong MY; McCaughan GW; Strasser SI
Expert Rev Gastroenterol Hepatol; 2017 Jun; 11(6):569-581. PubMed ID: 28317394
[TBL] [Abstract][Full Text] [Related]
27. Adenylyl cyclase 5 links changes in calcium homeostasis to cAMP-dependent cyst growth in polycystic liver disease.
Spirli C; Mariotti V; Villani A; Fabris L; Fiorotto R; Strazzabosco M
J Hepatol; 2017 Mar; 66(3):571-580. PubMed ID: 27826057
[TBL] [Abstract][Full Text] [Related]
28. The zebrafish as a model to study polycystic liver disease.
Tietz Bogert PS; Huang BQ; Gradilone SA; Masyuk TV; Moulder GL; Ekker SC; Larusso NF
Zebrafish; 2013 Jun; 10(2):211-7. PubMed ID: 23668934
[TBL] [Abstract][Full Text] [Related]
29. Effects of angiogenic factor overexpression by human and rodent cholangiocytes in polycystic liver diseases.
Fabris L; Cadamuro M; Fiorotto R; Roskams T; Spirlì C; Melero S; Sonzogni A; Joplin RE; Okolicsanyi L; Strazzabosco M
Hepatology; 2006 May; 43(5):1001-12. PubMed ID: 16628643
[TBL] [Abstract][Full Text] [Related]
30. Bile acid receptors in the biliary tree: TGR5 in physiology and disease.
Deutschmann K; Reich M; Klindt C; Dröge C; Spomer L; Häussinger D; Keitel V
Biochim Biophys Acta Mol Basis Dis; 2018 Apr; 1864(4 Pt B):1319-1325. PubMed ID: 28844960
[TBL] [Abstract][Full Text] [Related]
31. Bile Acids in Polycystic Liver Diseases: Triggers of Disease Progression and Potential Solution for Treatment.
Perugorria MJ; Labiano I; Esparza-Baquer A; Marzioni M; Marin JJ; Bujanda L; Banales JM
Dig Dis; 2017; 35(3):275-281. PubMed ID: 28249268
[TBL] [Abstract][Full Text] [Related]
32. Defects in cholangiocyte fibrocystin expression and ciliary structure in the PCK rat.
Masyuk TV; Huang BQ; Ward CJ; Masyuk AI; Yuan D; Splinter PL; Punyashthiti R; Ritman EL; Torres VE; Harris PC; LaRusso NF
Gastroenterology; 2003 Nov; 125(5):1303-10. PubMed ID: 14598246
[TBL] [Abstract][Full Text] [Related]
33. Synthetic Conjugates of Ursodeoxycholic Acid Inhibit Cystogenesis in Experimental Models of Polycystic Liver Disease.
Caballero-Camino FJ; Rivilla I; Herraez E; Briz O; Santos-Laso A; Izquierdo-Sanchez L; Lee-Law PY; Rodrigues PM; Munoz-Garrido P; Jin S; Peixoto E; Richard S; Gradilone SA; Perugorria MJ; Esteller M; Bujanda L; Marin JJG; Banales JM; Cossío FP
Hepatology; 2021 Jan; 73(1):186-203. PubMed ID: 32145077
[TBL] [Abstract][Full Text] [Related]
34. Diagnosis and management of polycystic liver disease.
Gevers TJ; Drenth JP
Nat Rev Gastroenterol Hepatol; 2013 Feb; 10(2):101-8. PubMed ID: 23296249
[TBL] [Abstract][Full Text] [Related]
35. Biliary infection may exacerbate biliary cystogenesis through the induction of VEGF in cholangiocytes of the polycystic kidney (PCK) rat.
Ren XS; Sato Y; Harada K; Sasaki M; Yoneda N; Lin ZH; Nakanuma Y
Am J Pathol; 2011 Dec; 179(6):2845-54. PubMed ID: 22015458
[TBL] [Abstract][Full Text] [Related]
36. Ursodeoxycholic acid alleviates experimental liver fibrosis involving inhibition of autophagy.
Ye HL; Zhang JW; Chen XZ; Wu PB; Chen L; Zhang G
Life Sci; 2020 Feb; 242():117175. PubMed ID: 31843528
[TBL] [Abstract][Full Text] [Related]
37. Hepato-renal pathology in pkd2ws25/- mice, an animal model of autosomal dominant polycystic kidney disease.
Stroope A; Radtke B; Huang B; Masyuk T; Torres V; Ritman E; LaRusso N
Am J Pathol; 2010 Mar; 176(3):1282-91. PubMed ID: 20093497
[TBL] [Abstract][Full Text] [Related]
38. Notch-Hes1 signaling activation in Caroli disease and polycystic liver disease.
Takahashi K; Sato Y; Yamamura M; Nakada S; Tamano Y; Sasaki M; Harada K
Pathol Int; 2021 Aug; 71(8):521-529. PubMed ID: 34166554
[TBL] [Abstract][Full Text] [Related]
39. Stat3-Atg5 signal axis inducing autophagy to alleviate hepatic ischemia-reperfusion injury.
Han YF; Zhao YB; Li J; Li L; Li YG; Li SP; Li ZD
J Cell Biochem; 2018 Apr; 119(4):3440-3450. PubMed ID: 29143976
[TBL] [Abstract][Full Text] [Related]
40. Ursodeoxycholic acid in advanced polycystic liver disease: A phase 2 multicenter randomized controlled trial.
D'Agnolo HM; Kievit W; Takkenberg RB; Riaño I; Bujanda L; Neijenhuis MK; Brunenberg EJ; Beuers U; Banales JM; Drenth JP
J Hepatol; 2016 Sep; 65(3):601-7. PubMed ID: 27212247
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
